442 related articles for article (PubMed ID: 33218742)
1. Naltrexone + Bupropion Combination for the Treatment of Binge-eating Disorder with Obesity: A Randomized, Controlled Pilot Study.
Grilo CM; Lydecker JA; Morgan PT; Gueorguieva R
Clin Ther; 2021 Jan; 43(1):112-122.e1. PubMed ID: 33218742
[TBL] [Abstract][Full Text] [Related]
2. Naltrexone plus bupropion combination medication maintenance treatment for binge-eating disorder following successful acute treatments: randomized double-blind placebo-controlled trial.
Grilo CM; Lydecker JA; Gueorguieva R
Psychol Med; 2023 Dec; 53(16):7775-7784. PubMed ID: 37366017
[TBL] [Abstract][Full Text] [Related]
3. Naltrexone-Bupropion and Behavior Therapy, Alone and Combined, for Binge-Eating Disorder: Randomized Double-Blind Placebo-Controlled Trial.
Grilo CM; Lydecker JA; Fineberg SK; Moreno JO; Ivezaj V; Gueorguieva R
Am J Psychiatry; 2022 Dec; 179(12):927-937. PubMed ID: 36285406
[TBL] [Abstract][Full Text] [Related]
4. Naltrexone/bupropion for binge-eating disorder: A randomized, double-blind, placebo-controlled trial.
Grilo CM; Lydecker JA; Jastreboff AM; Pittman B; McKee SA
Obesity (Silver Spring); 2023 Nov; 31(11):2762-2773. PubMed ID: 37751990
[TBL] [Abstract][Full Text] [Related]
5. Concurrent Improvement in Both Binge Eating and Depressive Symptoms with Naltrexone/Bupropion Therapy in Overweight or Obese Subjects with Major Depressive Disorder in an Open-Label, Uncontrolled Study.
Guerdjikova AI; Walsh B; Shan K; Halseth AE; Dunayevich E; McElroy SL
Adv Ther; 2017 Oct; 34(10):2307-2315. PubMed ID: 28918581
[TBL] [Abstract][Full Text] [Related]
6. Treatment of binge eating disorder in racially and ethnically diverse obese patients in primary care: randomized placebo-controlled clinical trial of self-help and medication.
Grilo CM; Masheb RM; White MA; Gueorguieva R; Barnes RD; Walsh BT; McKenzie KC; Genao I; Garcia R
Behav Res Ther; 2014 Jul; 58():1-9. PubMed ID: 24857821
[TBL] [Abstract][Full Text] [Related]
7. Orlistat with behavioral weight loss for obesity with versus without binge eating disorder: randomized placebo-controlled trial at a community mental health center serving educationally and economically disadvantaged Latino/as.
Grilo CM; White MA
Behav Res Ther; 2013 Mar; 51(3):167-75. PubMed ID: 23376451
[TBL] [Abstract][Full Text] [Related]
8. An open-label trial on the efficacy and tolerability of naltrexone/bupropion SR for treating altered eating behaviours and weight loss in binge eating disorder.
Carbone EA; Caroleo M; Rania M; Calabrò G; Staltari FA; de Filippis R; Aloi M; Condoleo F; Arturi F; Segura-Garcia C
Eat Weight Disord; 2021 Apr; 26(3):779-788. PubMed ID: 32356145
[TBL] [Abstract][Full Text] [Related]
9. Bupropion for overweight women with binge-eating disorder: a randomized, double-blind, placebo-controlled trial.
White MA; Grilo CM
J Clin Psychiatry; 2013 Apr; 74(4):400-6. PubMed ID: 23656848
[TBL] [Abstract][Full Text] [Related]
10. Predicting meaningful outcomes to medication and self-help treatments for binge-eating disorder in primary care: The significance of early rapid response.
Grilo CM; White MA; Masheb RM; Gueorguieva R
J Consult Clin Psychol; 2015 Apr; 83(2):387-94. PubMed ID: 25622201
[TBL] [Abstract][Full Text] [Related]
11. Psychiatric adverse events and effects on mood with prolonged-release naltrexone/bupropion combination therapy: a pooled analysis.
Pi-Sunyer X; Apovian CM; McElroy SL; Dunayevich E; Acevedo LM; Greenway FL
Int J Obes (Lond); 2019 Oct; 43(10):2085-2094. PubMed ID: 30664661
[TBL] [Abstract][Full Text] [Related]
12. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II).
Apovian CM; Aronne L; Rubino D; Still C; Wyatt H; Burns C; Kim D; Dunayevich E;
Obesity (Silver Spring); 2013 May; 21(5):935-43. PubMed ID: 23408728
[TBL] [Abstract][Full Text] [Related]
13. Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo.
Greenway FL; Dunayevich E; Tollefson G; Erickson J; Guttadauria M; Fujioka K; Cowley MA;
J Clin Endocrinol Metab; 2009 Dec; 94(12):4898-906. PubMed ID: 19846734
[TBL] [Abstract][Full Text] [Related]
14. Cognitive-behavioral therapy for binge-eating disorder for non-responders to initial acute treatments: Randomized controlled trial.
Grilo CM; Lydecker JA; Gueorguieva R
Int J Eat Disord; 2023 Aug; 56(8):1544-1553. PubMed ID: 37144325
[TBL] [Abstract][Full Text] [Related]
15. 12-month follow-up of fluoxetine and cognitive behavioral therapy for binge eating disorder.
Grilo CM; Crosby RD; Wilson GT; Masheb RM
J Consult Clin Psychol; 2012 Dec; 80(6):1108-13. PubMed ID: 22985205
[TBL] [Abstract][Full Text] [Related]
16. Treatment of binge eating disorder.
Wilson GT
Psychiatr Clin North Am; 2011 Dec; 34(4):773-83. PubMed ID: 22098803
[TBL] [Abstract][Full Text] [Related]
17. Study protocol and rationale for a randomized double-blinded crossover trial of phentermine-topiramate ER versus placebo to treat binge eating disorder and bulimia nervosa.
Dalai SS; Adler S; Najarian T; Safer DL
Contemp Clin Trials; 2018 Jan; 64():173-178. PubMed ID: 29038069
[TBL] [Abstract][Full Text] [Related]
18. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Greenway FL; Fujioka K; Plodkowski RA; Mudaliar S; Guttadauria M; Erickson J; Kim DD; Dunayevich E;
Lancet; 2010 Aug; 376(9741):595-605. PubMed ID: 20673995
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological treatment of binge eating disorder: update review and synthesis.
Reas DL; Grilo CM
Expert Opin Pharmacother; 2015; 16(10):1463-78. PubMed ID: 26044518
[TBL] [Abstract][Full Text] [Related]
20. Naltrexone/bupropion for the treatment of obesity and obesity with Type 2 diabetes.
Apovian CM
Future Cardiol; 2016 Mar; 12(2):129-38. PubMed ID: 26679384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
